Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application

By In The News
June 26, 2022 in The Headlines

Followers 0

Recommended Posts

In The News

Posted June 26, 2022

- Share

Posted June 26, 2022

SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the...

View the full article

Link to comment

Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign in

Already have an account? Sign in here.

Followers 0

Go to topic listing

Most Contributions
1. In The News
  223018
2. Jaydee
  18411
3. deicer
  13912
4. Kip Powick
  12396
5. dagger
  9619
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  273.5k
- Total Posts
  
  568k

Sign In

Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application

Recommended Posts

In The News

Link to comment

Share on other sites

Create an account or sign in to comment

Create an account

Sign in

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support